These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 11069208)

  • 21. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes.
    Marino MT; Costello D; Baughman R; Boss A; Cassidy J; Damico C; van Marle S; van Vliet A; Richardson PC
    Clin Pharmacol Ther; 2010 Aug; 88(2):243-50. PubMed ID: 20592721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
    Vaag AA; Holst JJ; Vølund A; Beck-Nielsen HB
    Eur J Endocrinol; 1996 Oct; 135(4):425-32. PubMed ID: 8921824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the role of the gut in diabetic hyperglucagonaemia.
    Lund A
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
    Nauck MA; Kleine N; Orskov C; Holst JJ; Willms B; Creutzfeldt W
    Diabetologia; 1993 Aug; 36(8):741-4. PubMed ID: 8405741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes.
    Christensen M; Knop FK; Vilsbøll T; Aaboe K; Holst JJ; Madsbad S; Krarup T
    Regul Pept; 2010 Aug; 163(1-3):96-101. PubMed ID: 20580750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.
    Elliott RM; Morgan LM; Tredger JA; Deacon S; Wright J; Marks V
    J Endocrinol; 1993 Jul; 138(1):159-66. PubMed ID: 7852887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus.
    Hare KJ; Knop FK; Asmar M; Madsbad S; Deacon CF; Holst JJ; Vilsbøll T
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4679-87. PubMed ID: 19837930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The change of glucagon-like peptide-1 and its effect on blood glucose metabolism after major surgery].
    Jia QB; Liu ZM; Peng B; Li SQ; Wu YT
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jan; 39(1):66-8, 88. PubMed ID: 18390203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
    Ritzel R; Schulte M; Pørksen N; Nauck MS; Holst JJ; Juhl C; März W; Schmitz O; Schmiegel WH; Nauck MA
    Diabetes; 2001 Apr; 50(4):776-84. PubMed ID: 11289042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
    Gutniak M; Orskov C; Holst JJ; Ahrén B; Efendic S
    N Engl J Med; 1992 May; 326(20):1316-22. PubMed ID: 1348845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of dysregulated glucagon secretion in type 2 diabetes.
    D'Alessio D
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():126-32. PubMed ID: 21824266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.
    Gutniak MK; Linde B; Holst JJ; Efendić S
    Diabetes Care; 1994 Sep; 17(9):1039-44. PubMed ID: 7988303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
    Vilsbøll T; Agersø H; Krarup T; Holst JJ
    J Clin Endocrinol Metab; 2003 Jan; 88(1):220-4. PubMed ID: 12519856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts.
    Barakat GM; Nuwayri-Salti N; Kadi LN; Bitar KM; Al-Jaroudi WA; Bikhazi AB
    Gen Physiol Biophys; 2011 Mar; 30(1):34-44. PubMed ID: 21460410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
    Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
    Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.
    D'Alessio DA; Kahn SE; Leusner CR; Ensinck JW
    J Clin Invest; 1994 May; 93(5):2263-6. PubMed ID: 8182159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.